Related Experiment Video
Updated: Dec 12, 2025
06:24
Minimal Erythema Dose MED Testing
Published on: May 28, 2013
42.6K
Palmar-plantar erythrodysesthesia associated with high-dose methotrexate: Case report
Priyanka Chauhan1, Anshul Gupta1, Sujeet Kumar1
1Department of Hematology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India.
Cancer Reports (Hoboken, N.J.)
|August 9, 2020
Summary
Palmar-plantar erythrodysesthesia (PPE) is a rare but severe side effect of methotrexate infusion. This case report details successful management of severe PPE in a Burkitt Lymphoma patient through conservative measures and dose reduction.
Area of Science:
- Oncology
- Pharmacology
- Dermatology
Background:
- Palmar-plantar erythrodysesthesia (PPE), also known as hand-foot syndrome, is a dose-limiting toxicity associated with various chemotherapy and targeted therapy agents.
- While PPE is documented with numerous systemic treatments, its occurrence with methotrexate infusion is infrequently reported in medical literature.
Observation:
- This report details a case of Burkitt Lymphoma presenting with severe PPE following methotrexate infusion.
- The patient experienced significant debilitating symptoms consistent with PPE.
Findings:
- The patient demonstrated a robust positive response to conservative management strategies.
- Subsequent dose reduction of methotrexate in following cycles led to the resolution of PPE symptoms, indicating effective management.
Implications:
- This case highlights the importance of recognizing and managing PPE, even when associated with less common agents like methotrexate.
- Conservative management and therapeutic adjustments, such as dose reduction, can effectively mitigate severe PPE, improving patient tolerability and treatment adherence.
- Further investigation into the mechanisms and optimal management of methotrexate-induced PPE is warranted.
